|Ms. Mary Anne Heino||CEO, Pres & Director||1.6M||N/A||1960|
|Mr. Robert J. Marshall Jr.||CFO & Treasurer||649.64k||N/A||1967|
|Mr. Michael P. Duffy||Sr. VP of Law & Public Policy and Gen. Counsel||716.89k||N/A||1961|
|Dr. Cesare Orlandi||Chief Medical Officer||639.45k||N/A||1950|
|Mr. John J. Bolla||Chief Operating Officer||N/A||N/A||1970|
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide a novel biomarker for clinical development and management of immuno-oncology therapies. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Lantheus Holdings, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 3.